Sumitomo Chemical Co. Ltd.
Sumitomo Pharma Co. Ltd.
Sumitovant Biopharma Ltd.
10% Owner | 2023-03-10 09:29:56 | 45,798,176
0 | 45,798,176 | Form 13D |
MILLENNIUM PHARMACEUTICALS INC
Takeda Pharmaceuticals U.S.A. Inc.
10% Owner | 2018-03-29 20:50:40 | 7,420,625
0 | 7,420,625 | Form 3 |
Takeda Pharmaceuticals International AG
TAKEDA PHARMACEUTICAL CO LTD
Takeda A/S
Takeda Europe Holdings B.V.
Takeda Pharma A/S
10% Owner | 2020-01-24 06:16:37 | 3,920,625
0 | 3,920,625 | Form 13G |
Seely Lynn
Principal Executive Officer | 2020-04-07 17:16:33 | 1,346,517
846,168 | 2,192,685 | Form 4 |
Sablich Kim
Chief Commercial Officer | 2020-04-07 17:14:42 | 281,174
0 | 281,174 | Form 4 |
KARBE FRANK
Principal Fin'l & Accounting | 2021-07-09 16:27:07 | 212,296
0 | 212,296 | Form 4 |
Torti Frank
Director | 2019-08-27 16:50:56 | 58,608
0 | 58,608 | Form 4 |
DeVeydt Wayne S
Director | 2017-10-20 16:46:51 | 22,500
0 | 22,500 | Form 4 |
Altmeyer Mark
Director | 2018-09-04 16:44:44 | 22,500
0 | 22,500 | Form 4 |
Sebelius Kathleen
Director | 2020-09-17 16:12:00 | 21,603
0 | 21,603 | Form 4 |
Romeo Marianne L.
Head,Global Trans. & Risk Mgmt | 2016-10-26 20:11:12 | 14,102
0 | 14,102 | Form 3 |
Gulfo Adele M.
Director | 2023-03-10 09:28:58 | 0
0 | 0 | Form 4 |
Arjona Ferreira Juan Camilo
Chief Medical Officer | 2023-03-10 09:24:59 | 0
0 | 0 | Form 4 |
Curran Terrie
Director | 2023-03-10 09:27:33 | 0
0 | 0 | Form 4 |
GUINAN MARK
Director | 2023-03-10 09:28:18 | 0
0 | 0 | Form 4 |
Roivant Sciences Ltd.
10% Owner | 2019-12-31 16:45:46 | 0
0 | 0 | Form 4 |
Lang Matthew
General Counsel & Corp. Secy. | 2023-03-10 09:29:36 | 0
0 | 0 | Form 4 |
Marek David C
Principal Executive Officer | 2023-03-10 09:30:13 | 0
0 | 0 | Form 4 |
Mehra Uneek
Principal Financial Officer | 2023-03-10 09:31:05 | 0
0 | 0 | Form 4 |
Merendino Lauren
Chief Commercial Officer | 2023-03-10 09:31:44 | 0
0 | 0 | Form 4 |
POTTER MYRTLE S
Director | 2023-03-10 09:32:18 | 0
0 | 0 | Form 4 |
Valente Nancy
Director | 2023-03-10 09:32:52 | 0
0 | 0 | Form 4 |
Nishinaka Shigeyuki
Director | 2022-10-21 17:15:29 | 0
0 | 0 | Form 3 |
Nomura Hiroshi
Director | 2019-12-30 17:15:03 | 0
0 | 0 | Form 3 |
Lo Andrew
Former 10% Owner | 2019-07-16 17:42:17 | 0
0 | 0 | Form 13D |
Machado Patrick
Former 10% Owner | 2019-07-16 17:31:17 | 0
0 | 0 | Form 13D |
Dexxon Holdings Ltd.
Dexcel Pharma Technologies Ltd.
Oren Dan
See remarks | 2019-07-12 16:52:12 | 0
0 | 0 | Form 4 |
VIKING GLOBAL PERFORMANCE LLC
Viking Global Equities LP
Viking Global Equities II LP
VGE III Portfolio Ltd.
Viking Global Equities Master Ltd.
Viking Long Fund GP LLC
Viking Long Fund Master Ltd.
HALVORSEN OLE ANDREAS
Ott David C.
Shabet Rose Sharon
Former 10% Owner | 2019-07-12 20:34:36 | 0
0 | 0 | Form 4 |
VIKING GLOBAL INVESTORS LP
Viking Global Opportunities Illiquid Investments Sub-Master LP
Viking Global Opportunities Portfolio GP LLC
Viking Global Opportunities GP LLC
HALVORSEN OLE ANDREAS
Ott David C.
Shabet Rose Sharon
Former 10% Owner | 2019-07-12 20:33:27 | 0
0 | 0 | Form 4 |
SVF Investments (UK) Ltd
SoftBank Vision Fund L.P.
SVF Holdings (UK) LLP
SVF GP (Jersey) Ltd
Former 10% Owner | 2019-07-12 19:50:26 | 0
0 | 0 | Form 4 |
QVT Associates GP LLC
QVT Fund V LP
10% Owner | 2019-07-12 16:28:55 | 0
0 | 0 | Form 4 |
VIKING GLOBAL INVESTORS LP
Viking Global Opportunities Illiquid Investments Sub-Master LP
Viking Global Opportunities Portfolio GP LLC
Viking Global Opportunities GP LLC
HALVORSEN OLE ANDREAS
Ott David C.
Sundheim Daniel S.
10% Owner | 2019-07-12 16:59:53 | 0
0 | 0 | Form 13D |
Ramaswamy Vivek
Director | 2016-10-26 20:17:40 | 0
0 | 0 | Form 3 |
MANCHESTER KEITH S
Director | 2016-10-26 20:13:55 | 0
0 | 0 | Form 3 |